We evaluated the prognostic value of quantitative parameters using dual time point (DTP) 18 F-FDG PET/CT (PET/CT) in invasive ductal breast cancer (IDC) with metastatic axillary lymph nodes (ALN) as compared with dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI. Seventy patients with IDC and metastatic ALN were retrospectively registered. Static PET parameters including maximum standardized uptake value (SUV max), metabolic tumor volume (MTV), total lesion glycolysis (TLG) of primary tumor, SUV max of ALN (SUV ALN), and percentage changes (Δ%) in those parameters were measured with DTP PET/CT. From DCE MRI, peak enhancement value, total tumor angio volume, and proportions of kinetic curve types on delayed-phases were investigated. The average apparent diffusion coefficient (ADC avg) was estimated on DWI. To demonstrate the prognostic value of quantitative imaging parameters for recurrence-free survival (RFS), univariate and multivariate analyses were performed using those parameters and clinicohistologic variables. All static PET parameters, %ΔSUV max, %ΔMTV, and %ΔSUV ALN on DTP PET/CT and ADC avg on DWI were significantly predictive for disease recurrence. Of clinicohistologic variables, pathologic tumor (pT) diameter, pathologic ALN stage, tumor grade, and hormonal status also were significantly prognostic. After multivariate analysis, %ΔSUV max > 25.05 (P =.043), ADC avg ≤ 1016.55 (P =.020), pT diameter > 3 cm (P =.001), and ER negative status (P =.002) were independent prognostic factors for poor outcome. Only %ΔSUV max of the primary tumor on PET/CT together with ADC avg, pT diameter, and ER status was an independent prognostic factor for predicting relapse in IDC with metastatic ALN. Percentage change of primary tumor on preoperative PET/CT may be a valuable imaging marker for selecting IDC patients that require adjunct treatment to prevent relapse.
- diffusion weighted imaging
- dual time point 18 F-FDG PET/CT
- dynamic contrast
- invasive ductal breast cancer
- magnetic resonance imaging
- recurrence-free survival